Total trials
1,667
Active
84
Phase 3
322
Total enrollment
24,906,412
Pipeline matrix
Showing 40 of 73 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Darolutamide | — | 20 | |||||
| Acoramidis | — | — | — | — | 2 | ||
| ARPI therapy | — | — | — | — | — | 1 | |
| Radium-223 dichloride | — | 30 | |||||
| Finerenone | — | 27 | |||||
| Pembrolizumab | — | — | — | 8 | |||
| Elinzanetant | — | — | — | 16 | |||
| Cisplatin | — | — | — | 7 | |||
| Carboplatin | — | — | — | 3 | |||
| Pemetrexed | — | — | — | — | 2 | ||
| BAY3723113 | — | — | — | — | — | 1 | |
| Riociguat | — | 30 | |||||
| Sevabertinib | — | — | — | 3 | |||
| Larotrectinib | — | — | — | 7 | |||
| ADT | — | — | — | — | 3 | ||
| BAY2927088 | — | — | — | — | 5 | ||
| AB-1005 | — | — | — | — | — | 1 | |
| BAY 3670549 | — | — | — | — | — | 1 | |
| BAY 3713372 | — | — | — | — | — | 1 | |
| BAY2927088_formulation A | — | — | — | — | — | 1 | |
| BAY2927088_formulation B_1 | — | — | — | — | — | 1 | |
| BAY2927088_formulation B_2 | — | — | — | — | — | 1 | |
| BAY2927088_formulation B_3 | — | — | — | — | — | 1 | |
| BAY 3401016 | — | — | — | — | — | 1 | |
| BAY2599023 | — | — | — | — | — | 1 | |
| Regorafenib | — | 45 | |||||
| BAY3389934 | — | — | — | — | — | 2 | |
| Nurandociguat | — | — | — | — | — | 2 | |
| Cetuximab | — | — | — | — | — | 2 | |
| BAY3498264 | — | — | — | — | — | 1 | |
| 225Ac-PSMA-Trillium | — | — | — | — | — | 1 | |
| BAY3375968 | — | — | — | — | — | 1 | |
| BAY3546828 | — | — | — | — | — | 1 | |
| BAY2965501 | — | — | — | — | — | 1 | |
| Platinum-based Chemotherapy | — | — | — | — | — | 1 | |
| BAY 3547926 | — | — | — | — | — | 1 | |
| BAY 3547922 | — | — | — | — | — | 1 | |
| BAY 3713391 | — | — | — | — | — | 1 | |
| BAY 3713389 | — | — | — | — | — | 1 | |
| Nitroglycerin spray | — | — | — | — | — | 1 |
33 more active programs hidden
Next readouts
- 2020-02-27
- 2020-03-07
- 2024-01-29
- 2024-07-20
- 2025-03-31
- 2025-05-30
- 2025-11-21
- 2025-12-10
- 2026-02-06
- 2026-03-16
Top conditions
- Contraception81
- Atrial Fibrillation52
- Sunscreening Agents52
- Hemophilia A48
- Erectile Dysfunction48
- Neoplasms44
- Chronic Kidney Disease33
- Multiple Sclerosis31
Frequently asked questions about Bayer
- How many clinical trials does Bayer have on ClinicalTrials.gov?
- Bayer is listed as the lead sponsor on 1,667 clinical trials in ClinicalTrials.gov, 84 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Bayer's trials are in Phase 3?
- 322 of Bayer's trials are in Phase 3, spread across 73 active drug programs.
- What therapeutic areas does Bayer focus on?
- Bayer's most-studied conditions on ClinicalTrials.gov are Contraception, Atrial Fibrillation, Sunscreening Agents, Hemophilia A, Erectile Dysfunction.
- When are Bayer's next clinical trial readouts?
- Bayer has 10 upcoming primary-completion readouts tracked here; the soonest is “Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib”, expected around 2020-02-27.